Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

First-Line Japan Alecensa Trial Stopped Early On Benefits

This article was originally published in Scrip

Executive Summary

A Japanese Phase III trial investigating the first-line use of Chugai Pharmaceutical Co. Ltd's alectinib in lung cancer has been halted early following better than expected positive results, boding well for the ALK inhibitor in this important setting.

You may also be interested in...



Novartis’ Zykadia ASCEND-4 Study Close But No Cigar In NSCLC

The presentation of the full data from Novartis’ ASCEND-4 study of Zykadia show decent efficacy in first-line NSCLC but are unlikely to be enough to overcome doctors’ caution over its tolerability profile, especially with rival Alecensa snapping at its heels.

Novartis’s Zykadia ASCENDs First-Line NSCLC Heights But Roche’s Alecensa Gives Chase

Novartis’s anticancer Zykadia is catching up its rival, Pfizer’s Xalkori, by showing a benefit when used first line in the Phase III ASCEND-4 study in NSCLC, but must still look over its shoulder at Roche’s Alecensa.

Pandemic Drives China Surge In Asia 100 Sales

Notable new entrants moved into the Asia 100 this year, with growth catalyzed by COVID-19 vaccines.

Topics

Latest News
See All
UsernamePublicRestriction

Register

SC064466

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel